logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa a retrospective cohort study

Ndjeka N, Campbell JR, Meintjes GA, Maartens G, Schaaf HS,  et al.
2022-05-02 • Lancet Infectious Diseases
2022-05-02 • Lancet Infectious Diseases
BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...
Journal Article
|
Research

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F,  et al.
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Journal Article
|
Research

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...
Journal Article
|
Research

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G,  et al.
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...
Journal Article
|
Research

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N,  et al.
2015-07-19 • International Journal of Tuberculosis and Lung Disease
2015-07-19 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.

OBJECTIVE
To descri...
Journal Article
|
Research

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

Schnippel K, Ndjeka N, Maartens G, Meintjes GA, Master I,  et al.
2018-09-01 • Lancet Respiratory Medicine
2018-09-01 • Lancet Respiratory Medicine
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Foll...
Journal Article
|
Letter

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?

Ndjeka N, Conradie F, Meintjes GA, Reuter A, Hughes J,  et al.
2020-07-23 • European Respiratory Journal
2020-07-23 • European Respiratory Journal
Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partner...
Journal Article
|
Commentary

Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis

Conradie F, Meintjes GA, Hughes J, Maartens G, Ferreira H,  et al.
2014-03-01 • South African Medical Journal
2014-03-01 • South African Medical Journal
While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a...